MSD’s KEYTRUDA® (pembrolizumab) significantly improved disease-free survival (DFS) versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) regardless of PD-L1 expression
BRUSSELS; KENILWORTH, N.J., Mar. 17, 2022 – MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA., the ...